Conaret

Leaflet attached to the packaging: patient information

Conaret, 1.25 mg, tablets

Conaret, 2.5 mg, tablets

Conaret, 3.75 mg, tablets

Conaret, 5 mg, tablets

Conaret, 7.5 mg, tablets

Conaret, 10 mg, tablets

Bisoprolol fumarate

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Conaret and what is it used for
• 2. Important information before taking Conaret
• 3. How to take Conaret
• 4. Possible side effects
• 5. How to store Conaret
• 6. Contents of the packaging and other information

1. What is Conaret and what is it used for

The active substance of Conaret is bisoprolol. Bisoprolol belongs to a group of medicines called beta-adrenergic blockers. These medicines affect the body's response to certain nerve impulses, especially in the heart. As a result, bisoprolol slows down the heart rate and increases the efficiency of the heart in pumping blood throughout the body. At the same time, it reduces the amount of blood needed by the heart and its oxygen consumption.
Conaret is used to treat stable, chronic heart failure. Heart failure occurs when the heart muscle is weak and cannot pump enough blood to meet the body's needs. It is used in combination with other medicines intended to treat this disease (such as angiotensin-converting enzyme inhibitors, diuretics, and cardiac glycosides).
In addition, Conaret 5 mg and 10 mg are used to treat high blood pressure (hypertension) and chest pain caused by reduced blood flow in the coronary arteries (coronary heart disease: angina pectoris).

2. Important information before taking Conaret

When not to take Conaret

• if you are allergic to bisoprolol fumarate or any of the other ingredients of this medicine (listed in section 6);
• if you have severe asthma;
• if you have advanced vascular disease, which reduces blood flow to the arms and legs (peripheral arterial occlusive disease);
• if you have severe circulatory disorders in the limbs (such as Raynaud's syndrome), which can cause tingling, pallor, or cyanosis of the fingers and toes;
• if you have an untreated pheochromocytoma (a rare tumor of the adrenal gland);
• if you have metabolic acidosis (a disorder that causes excessive accumulation of acids in the blood).

You should not take Conaret if you have the following heart conditions:

• acute heart failure;
• worsening of heart failure that requires intravenous administration of medicines that increase the strength of heart contractions;
• slow heart rate (less than 50 contractions per minute);
• low blood pressure (systolic blood pressure below 90 mmHg);
• certain heart rhythm disorders that cause very slow or irregular heartbeats;
• cardiogenic shock (severe heart condition that causes low blood pressure and circulatory failure). If in doubt, whether any of the above conditions apply to you, consult a doctor.

Warnings and precautions

If you have any of the following conditions, you should discuss them with your doctor or pharmacist before taking Conaret; the doctor or pharmacist may decide that special caution is necessary (e.g., additional medication or more frequent monitoring):

• diabetes;
• strict fasting;
• certain heart diseases, such as heart rhythm disorders or severe chest pain at rest (Prinzmetal's angina);
• kidney or liver disorders;
• not very severe circulatory disorders in the limbs;
• chronic lung disease or not very severe asthma;
• the occurrence of scaly skin lesions (psoriasis), also in the past;
• adrenal gland tumor (pheochromocytoma).
• thyroid dysfunction.

In addition, you should tell your doctor if you are planning:

• desensitization treatment (e.g., to avoid hay fever), as Conaret may increase the risk of an allergic reaction or increase its severity;
• surgery under general anesthesia, as Conaret may change the body's response to the administered medicines.

If you have chronic lung disease or not very severe asthma, you should immediately tell your doctor if you experience new breathing difficulties, cough, wheezing after physical exertion, etc. while taking Conaret.

Children and adolescents

Conaret is not recommended for use in children and adolescents.

Conaret and other medicines

You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
You should not take the following medicines with Conaret without special recommendation by your doctor:

• certain medicines used to treat heart rhythm disorders (class I anti-arrhythmic medicines, such as quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone);
• certain medicines used to treat high blood pressure, angina pectoris, or heart rhythm disorders (calcium antagonists, such as verapamil and diltiazem);
• certain medicines used to treat high blood pressure, such as clonidine, methyldopa, moxonidine, rilmenidine. However, you should not stop taking these medicines without consulting your doctor.

Before taking the following medicines with Conaret, you should discuss them with your doctor, as your doctor may recommend more frequent medical check-ups:

• certain medicines used to treat high blood pressure or angina pectoris (calcium antagonists of the dihydropyridine type, such as felodipine and amlodipine);
• certain medicines used to treat heart rhythm disorders (class III anti-arrhythmic medicines, such as amiodarone);
• locally used beta-adrenergic blockers (such as eye drops for glaucoma treatment);
• certain medicines used to treat, for example, Alzheimer's disease or glaucoma (parasympathomimetics, such as tacrine or carbachol) or medicines used to treat acute heart disorders (sympathomimetics, such as isoprenaline, dobutamine, and orciprenaline); antidiabetic medicines, including insulin;
• medicines used for general anesthesia (e.g., during surgery);
• digitalis glycosides used to treat heart failure;
• non-steroidal anti-inflammatory medicines (NSAIDs) used to treat arthritis, relieve pain, and reduce inflammation (e.g., ibuprofen and diclofenac);
• all medicines that can lower blood pressure, either as a desired or undesired effect, such as antihypertensive medicines, certain antidepressants (tricyclic antidepressants), certain antiepileptic medicines, or medicines used during general anesthesia (barbiturates, such as phenobarbital), and certain medicines used for psychiatric disorders characterized by loss of contact with reality (phenothiazine derivatives, e.g., levomepromazine);
• mefloquine, used to prevent and treat malaria;
• medicines used to treat depression, called monoamine oxidase inhibitors (except for MAO-B inhibitors), such as moklobemide.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before taking this medicine.
Pregnancy
There is a risk that taking Conaret during pregnancy may harm the baby.
If you are pregnant or plan to become pregnant, you should tell your doctor. Your doctor will decide whether you can take Conaret during pregnancy.
Breastfeeding
It is not known whether bisoprolol passes into breast milk, so it is not recommended to take Conaret during breastfeeding.

Driving and using machines

The medicine, depending on how it is tolerated, may impair the ability to drive or operate machines. You should be particularly careful at the beginning of treatment, after increasing the dose, or when changing medicines, as well as when combining the medicine with alcohol.

3. How to take Conaret

This medicine should always be taken exactly as prescribed by your doctor. If you are unsure, consult your doctor or pharmacist.
During treatment with Conaret, regular medical check-ups are necessary. This is especially important at the beginning of treatment, during dose increase, and when stopping treatment.
The tablet should be taken in the morning with food or independently of food, washed down with water. The tablets should not be crushed or chewed. The dividing line on the tablet is not intended for breaking the tablet.
Conaret treatment is usually long-term.

Chronic heart failure

Adults, including the elderly
Bisoprolol treatment starts with small doses, which are then gradually increased.
Your doctor will decide how to increase the dose. This is usually done as follows:

• 1.25 mg of bisoprolol once a day for a week
• 2.5 mg of bisoprolol once a day for a week
• 3.75 mg of bisoprolol once a day for a week
• 5 mg of bisoprolol once a day for four weeks
• 7.5 mg of bisoprolol once a day for four weeks
• 10 mg of bisoprolol once a day for maintenance treatment.

The maximum recommended dose is 10 mg of bisoprolol per day.
If Conaret 1.25 mg, 3.75 mg, or 7.5 mg is not marketed in your country, these doses can be achieved using other available bisoprolol products.
Depending on how the medicine is tolerated, your doctor may decide to extend the time between dose increases. If the disease worsens or the medicine is not tolerated, it may be necessary to reduce the dose again or stop treatment. In some patients, a lower maintenance dose than 10 mg of bisoprolol may be sufficient. Your doctor will determine the appropriate course of action.
If treatment needs to be stopped, your doctor will usually recommend gradually reducing the dose of the medicine; otherwise, the disease may worsen.

High blood pressure (hypertension)

Adults, including the elderly
Unless your doctor recommends otherwise, the recommended dose is 5 mg of bisoprolol once a day. In milder cases of hypertension (diastolic blood pressure up to 105 mmHg), 2.5 mg once a day may be appropriate, using other medicines of suitable potency.
If necessary, the dose can be increased to 10 mg of bisoprolol per day. Further dose increases are only justified in exceptional cases.
The maximum recommended dose is 20 mg once a day.

Coronary heart disease (angina pectoris)

Adults, including the elderly
Unless your doctor recommends otherwise, the recommended dose is 5 mg of bisoprolol once a day.
If necessary, the dose can be increased to 10 mg of bisoprolol per day. Further dose increases are only justified in exceptional cases.
The maximum recommended dose is 20 mg once a day.

High blood pressure (hypertension) and coronary heart disease (angina pectoris)

Dosing in patients with liver or kidney disorders
In patients with mild to moderate liver or kidney disorders, there is usually no need to modify the dose. In patients with severe kidney disorders (creatinine clearance <20 ml min) or severe liver disorders, a dose greater than 10 mg of bisoprolol fumarate per day should not be used.< p>

Taking a higher dose of Conaret than recommended

In case of taking more tablets of Conaret than recommended, you should immediately contact your doctor. Your doctor will decide what actions to take.
Overdose symptoms may include slow heart rate, breathing difficulties, dizziness, or tremors (caused by low blood sugar levels).

Missing a dose of Conaret

You should not take a double dose to make up for a missed dose. You should take your usual dose the next morning.

Stopping Conaret treatment

You should not stop taking Conaret unless your doctor recommends it. Otherwise, it may cause significant worsening of symptoms.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.

4. Possible side effects

Like all medicines, Conaret can cause side effects, although not everybody gets them.
To prevent serious reactions, you should contact your doctor if side effects are severe, sudden, or worsening rapidly.

The most serious side effects are related to heart function:

• slow heart rate (may occur in more than 1 in 10 people - in patients with chronic heart failure; may occur in less than 1 in 100 people - in patients with hypertension or angina pectoris);
• worsening of heart failure (may occur in less than 1 in 10 people);
• slow or irregular heart rate (may occur in less than 1 in 100 people).

If you experience dizziness, weakness, or breathing difficulties, you should contact your doctor as soon as possible.
The remaining side effects are presented below, according to their frequency of occurrence.
Frequent(may occur in less than 1 in 10 people):

• feeling of fatigue, weakness (in patients with chronic heart failure), dizziness, headaches;
• feeling of cold or numbness in the hands or feet;
• low blood pressure;
• gastrointestinal disorders, such as nausea, vomiting, diarrhea, or constipation. These symptoms usually occur at the beginning of treatment and are mild and resolve within 1 to 2 weeks after starting treatment.

Uncommon(may occur in less than 1 in 100 people):

• feeling of weakness (in patients with hypertension or angina pectoris);
• sleep disorders;
• depression;
• dizziness when standing up;
• breathing difficulties in patients with asthma or chronic lung disease;
• muscle weakness or cramps.

Rare(may occur in less than 1 in 1000 people):

• hearing disorders;
• allergic rhinitis;
• reduced tear secretion (important if you wear contact lenses);
• liver inflammation, which can cause yellowing of the skin or whites of the eyes;
• changes in the results of some blood tests, related to liver function or blood lipid levels;
• allergic reactions, such as itching, flushing, rash. You should immediately contact your doctor if you experience more severe allergic reactions, which may include swelling of the face, neck, tongue, mouth, or throat, or difficulty breathing.
• reduced sexual potency;
• nightmares, hallucinations;
• fainting.

Very rare(may occur in less than 1 in 10,000 people):

• eye irritation or conjunctivitis;
• hair loss;
• the occurrence or worsening of scaly skin lesions (psoriasis), psoriasis-like changes.

Reporting side effects

If you experience any side effects, including those not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.

5. How to store Conaret

The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month stated.
Tablets packaged in OPA/Aluminium/PVC/Aluminium blisters:
Store in a temperature below 30°C. Store in the original packaging to protect from moisture.
Tablets packaged in white PVC/PVDC/Aluminium blisters:
Store in a temperature below 25°C. Store in the original packaging to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Conaret contains

The active substance of Conaret is bisoprolol fumarate.
Conaret, 1.25 mg, tablets: each tablet contains 1.25 mg of bisoprolol fumarate.
Conaret, 2.5 mg, tablets: each tablet contains 2.5 mg of bisoprolol fumarate.
Conaret, 3.75 mg, tablets: each tablet contains 3.75 mg of bisoprolol fumarate.
Conaret, 5 mg, tablets: each tablet contains 5 mg of bisoprolol fumarate.
Conaret, 7.5 mg, tablets: each tablet contains 7.5 mg of bisoprolol fumarate.
Conaret, 10 mg, tablets: each tablet contains 10 mg of bisoprolol fumarate.
The other ingredients of the medicine are: microcrystalline cellulose (type 102), cornstarch, crospovidone (type A), colloidal anhydrous silica, magnesium stearate.
Conaret, 3.75 mg, tablets, Conaret, 5 mg, tablets, Conaret, 7.5 mg, tablets, Conaret, 10 mg, tablets contain yellow iron oxide (E172);
Conaret, 3.75 mg, tablets, Conaret, 10 mg, tablets contain brown iron oxide (E172).

What Conaret looks like and contents of the pack

Conaret 1.25 mg, tablets: white, round tablets, with the inscription 1.25, with a diameter of 6 mm ± 0.3 mm.
Conaret, 2.5 mg, tablets: white, round tablets, with the inscription 2.5, with a dividing line, with a diameter of 6 mm ± 0.3 mm. The dividing line on the tablet is not intended for breaking the tablet.
Conaret, 3.75 mg, tablets: white to light beige, round tablets, with the inscription 3.75 and randomly distributed colorant spots, with a diameter of 6 mm ± 0.3 mm.
Conaret, 5 mg, tablets: yellow to light yellow, round tablets, with the inscription 5, with a dividing line and randomly distributed colorant spots, with a diameter of 6 mm ± 0.3 mm. The dividing line on the tablet is not intended for breaking the tablet.
Conaret, 7.5 mg, tablets: yellow to dark yellow, round tablets, with the inscription 7.5 and possible darker or lighter spots, with a diameter of 6 mm ± 0.3 mm.
Conaret, 10 mg, tablets: ochre-colored, round tablets, with the inscription 10, with a dividing line and possible darker or lighter spots, with a diameter of 6 mm ± 0.3 mm. The dividing line on the tablet is not intended for breaking the tablet.
Tablets 1.25 mg
Tablets are available in OPA/Aluminium/PVC/Aluminium blisters in a cardboard box.
Tablets 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg
Tablets are available in OPA/Aluminium/PVC/Aluminium or PVC/PVDC/Aluminium blisters in a cardboard box.
Available pack sizes:
1.25 mg: 20, 28, 30, 60, 90, or 100 tablets.
2.5 mg: 15, 28, 30, 60, 90, or 100 tablets.
3.75 mg: 28, 30, 50, 90, or 100 tablets.
5 mg; 10 mg: 28, 30, 50, 56, 60, 90, or 100 tablets.
7.5 mg: 28, 30, 50, 56, 60, or 100 tablets.
Not all pack sizes may be marketed.

Marketing authorization holder

Zentiva k.s.
U kabelovny 130
Dolni Mĕcholupy
102 37 Prague 10
Czech Republic

Manufacturer

Tablets 1.25, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg
Zentiva k.s.
U Kabelovny 130
Dolní Měcholupy
102 37 Prague 10
Czech Republic
Tablets 2.5 mg, 5 mg, 10 mg
S.C. Zentiva S.A.
B-dul Theodor Pallady nr 50, Sector 3
032266 Bucharest
Romania

This medicinal product is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:

Germany, Czech Republic, Bulgaria, Poland, Romania, Slovakia: Conaret
Austria, Portugal, Spain, Estonia, Latvia, Denmark, Norway, Sweden, Ireland: Bisoprolol Zentiva
Lithuania, United Kingdom (Northern Ireland): Bisoprolol fumarate Zentiva
France: BISOPROLOL ZENTIVA K.S
Italy: Bisoprololo Zentiva Generics

To obtain more detailed information, you should contact the representative of the marketing authorization holder in Poland:

Zentiva Polska Sp. z o.o.
ul. Bonifraterska 17
00-203 Warsaw
phone: +48 22 375 92 00
Date of last revision of the leaflet:September 2023